The Medicines Company (MDCO)

Company Description

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in cardiovascular events such PTCA and stenting; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. Products under development include MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP.



The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 U.S.A
United States

Toll-free: 800-388-1183


Get BioInvest's perspective on the Medicines Company's CEO

Latest Company News

Revenue Approximations Analysis: The Medicines Company (MDCO), Versar, Inc. (VSR) StockNewsJournal - Mar 23, 2017 The Medicines Company (MDCO) have shown a high EPS growth of -22.20% in the last 5 years and has earnings decline of 48.60% yoy. [...]
Thu, Mar 23, 2017 2:48:00 PM, Continue reading at the source
How This Company Is Taking on Amgen Motley Fool - Mar 23, 2017 The Medicines Company (NASDAQ:MDCO) recently announced positive phase 2 trial data for its cholesterol lowering drug, inclisiran, and if inclisiran can duplicate those results in a larger phase 3 study, then it could end up challenging Amgen ... Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can - Investor's Business Daily [...]
Thu, Mar 23, 2017 12:56:00 PM, Continue reading at the source
As Amgen Goes, So Goes Medicines Company Seeking Alpha - Mar 20, 2017 If Amgen (NASDAQ:AMGN) had a bad day on Friday with the release of long-awaited outcomes data for its cholesterol drug Repatha, then consider the Medicines Company (NASDAQ:MDCO). Its phase II project modulating the same biological pathway as ... HC Wainwright Reiterates “Buy” Rating for The Medicines Company (MDCO) - The Cerbat Gem Hot Stock to Watch: The Medicines Company (MDCO) - HugoPress [...]
Mon, Mar 20, 2017 6:33:00 PM, Continue reading at the source
Why Investors remained confident on Rite Aid Corporation (RAD), The Medicines ... StockNewsJournal - Mar 20, 2017 The Medicines Company (NASDAQ:MDCO), at its latest closing price of $48.38, it has a price-to-book ratio of 5.75, compared to an industry average at 4.05. [...]
Mon, Mar 20, 2017 4:18:00 PM, Continue reading at the source
The Medicines Company and Alnylam Pharmaceuticals Report Positive Final ... Yahoo Finance - Mar 17, 2017 The Medicines Company (MDCO) and Alnylam Pharmaceuticals, Inc. (ALNY) today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment ... LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1 - Medscape Alnylam touts latest trial data as suggesting its drugs are safe - Boston Business Journal [...]
Fri, Mar 17, 2017 4:26:00 PM, Continue reading at the source
The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of ... Business Wire (press release) - Mar 14, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneously with the presentation, the detailed results from its ORION-1 Phase II study of inclisiran, the Company's ... [...]
Tue, Mar 14, 2017 10:52:00 AM, Continue reading at the source
The Medicines Company to Host Conference Call and Webcast at Upcoming American ... Yahoo Finance - Mar 6, 2017 The Medicines Company (MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company's PCSK9 synthesis inhibitor. [...]
Mon, Mar 06, 2017 12:00:00 PM, Continue reading at the source
The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results Yahoo Finance - Feb 28, 2017 “Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D. [...]
Tue, Feb 28, 2017 12:00:00 PM, Continue reading at the source
Earnings Reaction History: The Medicines Company, 44.4% Follow-Through ... Nasdaq - Feb 28, 2017 The Medicines Company ( MDCO ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. [...]
Tue, Feb 28, 2017 11:26:00 AM, Continue reading at the source
The Medicines Company Partnering Deals and Alliances 2010 to 2017 PR Newswire (press release) - Feb 27, 2017 Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value. [...]
Mon, Feb 27, 2017 11:26:00 PM, Continue reading at the source